PaclitaxelAn Update of its Use in the Treatment of Metastatic Breast Cancer and Ovarian and Other Gynaecological Cancers

被引:0
作者
Lynda R. Wiseman
Caroline M. Spencer
机构
[1] Adis International Limited,
来源
Drugs & Aging | 1998年 / 12卷
关键词
Ovarian Cancer; Paclitaxel; Doxorubicin; Adis International Limited; Clin Oncol;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
页码:305 / 334
页数:29
相关论文
共 448 条
[21]  
Ibrado AM(1996)Potentiation of antitumor efficacy of paclitaxel by recombinant tumor necrosis factor-α Cancer Lett 103 183-90
[22]  
Ponnathpur V(1996)Ascorbic acid (vitamin C) improves the antineoplastic activity of doxorubicin, cisplatin, and paclitaxel in human breast carcinoma cells in vitro Gynecol Oncol 60 117-53
[23]  
Reed J(1995)Paclitaxel is only a weak radiosensitizer of human cervical carcinoma cell lines Gynecol Oncol 57 165-208
[24]  
Milas L(1996)Paclitaxel: a radiation sensitizer of human cervical cancer cells Curr Ther Res Clin Exp 57 430-93
[25]  
Hunter NR(1997)Sensitization of human uterine cervical cancer cells to radiation using paclitaxel Anticancer Res 17 939-7
[26]  
Kurdoglu B(1997)Vulvar squamous cell carcinoma cell lines are sensitive to paclitaxel J Clin Invest 100 1282-9
[27]  
Belotti D(1995)Taxol-resistant epithelial ovarian tumors are associated with altered expression of specific beta-tubulin isotypes N Engl J Med 332 1004-704
[28]  
Rieppi M(1995)Paclitaxel (Taxol) J Clin Oncol 13 180-15
[29]  
Nicoletti MI(1995)Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/pharmacodynamic relationships in humans Clin Drug Invest 9 344-21
[30]  
Klaassen U(1993)Limited sampling strategies for investigating paclitaxel pharmacokinetics in patients receiving 175 mg/m Cancer Surv 18 199-703